What is TREMFYA and what disease was it tested for?

TREMFYA is an immunology drug tested for perianal fistulizing Crohn's disease, with positive Phase 3 results being the first successful trial in 20 years.

What is the OTTAVA robotic surgical system?

OTTAVA is a robotic surgical system developed by Johnson & Johnson, for which the company released first-in-human data.

Johnson & Johnson Expands Clinical Pipeline in Immunology, MedTech, and AI

Johnson & Johnson (JNJ) reported new clinical results in immunology, MedTech, and neuropsychiatry, including pivotal Phase 3 data for TREMFYA in perianal fistulizing Crohn's disease and first-in-human data for the OTTAVA robotic surgical system.

By: Wrqti Editorial

May 5, 2026

2 min read

Source: Simply Wall St.

Key Numbers

phase3 trial

First successful in 20 years

Johnson & Johnson (NYSE:JNJ) announced new clinical results in immunology, MedTech, and neuropsychiatry, expanding its clinical pipeline in these critical areas.

Announcement Details

Phase 3 Data for TREMFYA

The company reported pivotal Phase 3 data for TREMFYA in perianal fistulizing Crohn's disease, marking the first successful randomized trial in this area in 20 years.

JNJ-4804 Results

Johnson & Johnson shared results for JNJ-4804 in highly refractory ulcerative colitis and Crohn's disease, supporting expanded Phase 3 programs.

OTTAVA Robotic Surgical System

In MedTech, the company released first-in-human data for the OTTAVA Robotic Surgical System, a significant step in robotic surgery development.

Pricing and Availability

Pricing and commercial availability details have not been announced yet.

Competition

Johnson & Johnson faces strong competition in immunology and MedTech from companies like AbbVie and Medtronic. However, positive TREMFYA results in a niche indication provide a competitive edge.

Potential Impact on the Company

These positive results are expected to strengthen Johnson & Johnson's position in the immunology and MedTech markets, potentially boosting future revenues.

Frequently Asked Questions

The company announced Phase 3 data for TREMFYA in perianal fistulizing Crohn's disease, results for JNJ-4804, and first-in-human data for the OTTAVA robotic surgical system.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.